KNIGHT THERAPEUTICS INC (GUD.CA) Stock Fundamental Analysis
TSX:GUD • CA4990531069
5.97 CAD
+0.07 (+1.19%)
Last: Feb 12, 2026, 07:00 PM
GUD gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 33 industry peers in the Pharmaceuticals industry. While GUD has a great health rating, there are worries on its profitability. GUD is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year GUD has reported negative net income.
- In the past year GUD had a positive cash flow from operations.
- The reported net income has been mixed in the past 5 years: GUD reported negative net income in multiple years.
- GUD had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
- GUD's Return On Assets of -0.33% is fine compared to the rest of the industry. GUD outperforms 66.67% of its industry peers.
- The Return On Equity of GUD (-0.46%) is better than 69.70% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.33% | ||
| ROE | -0.46% | ||
| ROIC | N/A |
ROA(3y)-1.39%
ROA(5y)0.29%
ROE(3y)-1.78%
ROE(5y)0.26%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- In the last couple of years the Profit Margin of GUD has declined.
- The Gross Margin of GUD (42.49%) is comparable to the rest of the industry.
- In the last couple of years the Gross Margin of GUD has declined.
- The Profit Margin and Operating Margin are not available for GUD so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 42.49% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-43.41%
PM growth 5Y-47.95%
GM growth 3Y-0.3%
GM growth 5Y-3.67%
2. Health
2.1 Basic Checks
- GUD does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for GUD has been reduced compared to 1 year ago.
- GUD has less shares outstanding than it did 5 years ago.
- The debt/assets ratio for GUD has been reduced compared to a year ago.
2.2 Solvency
- GUD has an Altman-Z score of 2.09. This is not the best score and indicates that GUD is in the grey zone with still only limited risk for bankruptcy at the moment.
- GUD has a better Altman-Z score (2.09) than 84.85% of its industry peers.
- GUD has a debt to FCF ratio of 37.42. This is a negative value and a sign of low solvency as GUD would need 37.42 years to pay back of all of its debts.
- Looking at the Debt to FCF ratio, with a value of 37.42, GUD is in the better half of the industry, outperforming 60.61% of the companies in the same industry.
- A Debt/Equity ratio of 0.11 indicates that GUD is not too dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.11, GUD is in the better half of the industry, outperforming 69.70% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | 37.42 | ||
| Altman-Z | 2.09 |
ROIC/WACCN/A
WACC9%
2.3 Liquidity
- A Current Ratio of 2.62 indicates that GUD has no problem at all paying its short term obligations.
- GUD has a better Current ratio (2.62) than 66.67% of its industry peers.
- A Quick Ratio of 1.68 indicates that GUD should not have too much problems paying its short term obligations.
- GUD's Quick ratio of 1.68 is fine compared to the rest of the industry. GUD outperforms 75.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.62 | ||
| Quick Ratio | 1.68 |
3. Growth
3.1 Past
- GUD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 93.10%, which is quite impressive.
- GUD shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -13.46% yearly.
- The Revenue has grown by 18.70% in the past year. This is quite good.
- Measured over the past years, GUD shows a very strong growth in Revenue. The Revenue has been growing by 50.87% on average per year.
EPS 1Y (TTM)93.1%
EPS 3Y-25.31%
EPS 5Y-13.46%
EPS Q2Q%-4850%
Revenue 1Y (TTM)18.7%
Revenue growth 3Y15.1%
Revenue growth 5Y50.87%
Sales Q2Q%31.74%
3.2 Future
- Based on estimates for the next years, GUD will show a very strong growth in Earnings Per Share. The EPS will grow by 54.92% on average per year.
- GUD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.98% yearly.
EPS Next Y-409.73%
EPS Next 2Y-2.05%
EPS Next 3Y41.41%
EPS Next 5Y54.92%
Revenue Next Year20.19%
Revenue Next 2Y14%
Revenue Next 3Y9.74%
Revenue Next 5Y9.98%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for GUD. In the last year negative earnings were reported.
- Based on the Price/Forward Earnings ratio of 124.44, the valuation of GUD can be described as expensive.
- GUD's Price/Forward Earnings ratio is in line with the industry average.
- GUD is valuated expensively when we compare the Price/Forward Earnings ratio to 27.96, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 124.44 |
4.2 Price Multiples
- The rest of the industry has a similar Enterprise Value to EBITDA ratio as GUD.
- Based on the Price/Free Cash Flow ratio, GUD is valued a bit cheaper than 60.61% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 208.79 | ||
| EV/EBITDA | 12.39 |
4.3 Compensation for Growth
- GUD's earnings are expected to grow with 41.41% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.05%
EPS Next 3Y41.41%
5. Dividend
5.1 Amount
- No dividends for GUD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TSX:GUD (2/12/2026, 7:00:00 PM)
5.97
+0.07 (+1.19%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)03-18 2026-03-18/amc
Inst Owners15.78%
Inst Owner ChangeN/A
Ins Owners1.88%
Ins Owner ChangeN/A
Market Cap592.76M
Revenue(TTM)413.85M
Net Income(TTM)-3.49M
Analysts78
Price Target8.09 (35.51%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-753.57%
Min EPS beat(2)-815.07%
Max EPS beat(2)-692.08%
EPS beat(4)2
Avg EPS beat(4)-169.96%
Min EPS beat(4)-815.07%
Max EPS beat(4)461.4%
EPS beat(8)2
Avg EPS beat(8)-354.72%
EPS beat(12)5
Avg EPS beat(12)-190.89%
EPS beat(16)7
Avg EPS beat(16)-395.3%
Revenue beat(2)2
Avg Revenue beat(2)11.78%
Min Revenue beat(2)11.06%
Max Revenue beat(2)12.49%
Revenue beat(4)4
Avg Revenue beat(4)8.38%
Min Revenue beat(4)0.88%
Max Revenue beat(4)12.49%
Revenue beat(8)7
Avg Revenue beat(8)5.34%
Revenue beat(12)11
Avg Revenue beat(12)8.81%
Revenue beat(16)14
Avg Revenue beat(16)8.72%
PT rev (1m)0.79%
PT rev (3m)1.71%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-250%
EPS NY rev (1m)4.17%
EPS NY rev (3m)-34.5%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.38%
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.68%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 124.44 | ||
| P/S | 1.43 | ||
| P/FCF | 208.79 | ||
| P/OCF | 16.67 | ||
| P/B | 0.77 | ||
| P/tB | 1.99 | ||
| EV/EBITDA | 12.39 |
EPS(TTM)-0.02
EYN/A
EPS(NY)0.05
Fwd EY0.8%
FCF(TTM)0.03
FCFY0.48%
OCF(TTM)0.36
OCFY6%
SpS4.17
BVpS7.72
TBVpS2.99
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.33% | ||
| ROE | -0.46% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 42.49% | ||
| FCFM | 0.69% |
ROA(3y)-1.39%
ROA(5y)0.29%
ROE(3y)-1.78%
ROE(5y)0.26%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-43.41%
PM growth 5Y-47.95%
GM growth 3Y-0.3%
GM growth 5Y-3.67%
F-Score5
Asset Turnover0.39
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | 37.42 | ||
| Debt/EBITDA | 1.93 | ||
| Cap/Depr | 58.99% | ||
| Cap/Sales | 7.91% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 80.91% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.62 | ||
| Quick Ratio | 1.68 | ||
| Altman-Z | 2.09 |
F-Score5
WACC9%
ROIC/WACCN/A
Cap/Depr(3y)40.08%
Cap/Depr(5y)130.51%
Cap/Sales(3y)6.77%
Cap/Sales(5y)24.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)93.1%
EPS 3Y-25.31%
EPS 5Y-13.46%
EPS Q2Q%-4850%
EPS Next Y-409.73%
EPS Next 2Y-2.05%
EPS Next 3Y41.41%
EPS Next 5Y54.92%
Revenue 1Y (TTM)18.7%
Revenue growth 3Y15.1%
Revenue growth 5Y50.87%
Sales Q2Q%31.74%
Revenue Next Year20.19%
Revenue Next 2Y14%
Revenue Next 3Y9.74%
Revenue Next 5Y9.98%
EBIT growth 1Y-395.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year454.5%
EBIT Next 3Y80.13%
EBIT Next 5Y55.6%
FCF growth 1Y-63.88%
FCF growth 3YN/A
FCF growth 5Y23.85%
OCF growth 1Y56.3%
OCF growth 3Y-6.66%
OCF growth 5Y51.14%
KNIGHT THERAPEUTICS INC / GUD.CA FAQ
Can you provide the ChartMill fundamental rating for KNIGHT THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 4 / 10 to GUD.CA.
What is the valuation status for GUD stock?
ChartMill assigns a valuation rating of 2 / 10 to KNIGHT THERAPEUTICS INC (GUD.CA). This can be considered as Overvalued.
What is the profitability of GUD stock?
KNIGHT THERAPEUTICS INC (GUD.CA) has a profitability rating of 2 / 10.
What is the financial health of KNIGHT THERAPEUTICS INC (GUD.CA) stock?
The financial health rating of KNIGHT THERAPEUTICS INC (GUD.CA) is 7 / 10.